In the current market climate, many publicly traded life sciences companies are evaluating their financing options. In this webinar, panelists from WilmerHale’s Capital Markets and Debt Finance practice groups discuss some of the capital raising alternatives companies might want to consider, including important considerations, advantages and limitations of each.
The discussion focuses on “at-the-market offerings” (ATMs), private investment in public equity (PIPEs) and registered direct offerings, equity lines, rights offerings, convertible debt offerings, and other debt finance options, as well as addresses other potential sources of liquidity.
*CLE credit is not available for those who watch webinar recordings.
